San Diego, CA, United States of America

Paul Andrew Wright

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Pfizer Vaccines, Lcc. Active years: 2014-2016.

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Paul Andrew Wright: Innovator in Immunology

Introduction

Paul Andrew Wright is a notable inventor based in San Diego, CA. He has made significant contributions to the field of immunology, particularly through his innovative work on vaccines. With a total of 2 patents, Wright has focused on developing novel immunogens that address IgE-mediated disorders.

Latest Patents

Wright's latest patents include the IgE CH3 peptide vaccine. This invention relates to the provision of novel immunogens comprising an antigenic IgE peptide, preferably linked to an immunogenic carrier. The compositions comprising these immunogens are designed for the prevention, treatment, or alleviation of IgE-mediated disorders. Furthermore, the invention outlines methods for the production of these medicaments, immunogenic compositions, and their use in medicine.

Career Highlights

Paul Andrew Wright is currently associated with Pfizer Vaccines, LLC, where he continues to advance his research and development efforts. His work is pivotal in creating effective solutions for immunological challenges.

Collaborations

Wright has collaborated with notable colleagues, including Brian Robert Champion and David Robert Stead. These partnerships have enhanced the scope and impact of his research.

Conclusion

Paul Andrew Wright stands out as an influential inventor in the field of immunology, with a focus on innovative vaccine development. His contributions are vital for addressing significant health challenges related to IgE-mediated disorders.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…